Zobrazeno 1 - 10
of 726
pro vyhledávání: '"Egbert, F Smit"'
Autor:
Franziska Böttger, Teodora Radonic, Idris Bahce, Kim Monkhorst, Sander R. Piersma, Thang V. Pham, Anne‐Marie C. Dingemans, Lisa M. Hillen, Mariacarmela Santarpia, Elisa Giovannetti, Egbert F. Smit, Sjaak A. Burgers, Connie R. Jimenez
Publikováno v:
Molecular Oncology, Vol 18, Iss 6, Pp 1417-1436 (2024)
The majority of patients with resected stage II‐IIIA non‐small cell lung cancer (NSCLC) are treated with platinum‐based adjuvant chemotherapy (ACT) in a one‐size‐fits‐all approach. However, a significant number of patients do not derive c
Externí odkaz:
https://doaj.org/article/59cc7532a44a481fb7f9c9573d143ffd
Autor:
Anastasia Gangaev, Yannick van Sleen, Nicole Brandhorst, Kelly Hoefakker, Bimal Prajapati, Amrita Singh, Annemarie Boerma, Marieke van der Heiden, Sjoukje F. Oosting, Astrid A. M. van der Veldt, T. Jeroen N. Hiltermann, Corine H. GeurtsvanKessel, Anne-Marie C. Dingemans, Egbert F. Smit, Elisabeth G. E. de Vries, John B. A. G. Haanen, Pia Kvistborg, Debbie van Baarle
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionResearch has confirmed the safety and comparable seroconversion rates following SARS-CoV-2 vaccination in patients with solid cancers. However, the impact of cancer treatment on vaccine-induced T cell responses remains poorly understood.M
Externí odkaz:
https://doaj.org/article/80fab91389fd443aa2a12002abce5698
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-13 (2024)
Abstract In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, BRAF sequencing approaches, and unmet needs. The BRAFV60
Externí odkaz:
https://doaj.org/article/5d4d7a8e57754e16812b1b989f4ffe66
Autor:
Suzanne M. Castenmiller, Nandhini Kanagasabesan, Aurélie Guislain, Benoît P. Nicolet, Marleen M. van Loenen, Kim Monkhorst, Alexander A.F.A. Veenhof, Egbert F. Smit, Koen J. Hartemink, John B.A.G. Haanen, Rosa de Groot, Monika C. Wolkers
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
Adoptive transfer of tumor infiltrating lymphocytes (TIL therapy) has proven highly effective for treating solid cancers, including non-small cell lung cancer (NSCLC). However, not all patients benefit from this therapy for yet unknown reasons. Defin
Externí odkaz:
https://doaj.org/article/765f3c5d599a4883af3b95a3fce40f0d
Autor:
Judith L. Gulikers, MSc, G.D. Marijn Veerman, MD, PhD, Merel Jebbink, MD, PhD, Paul D. Kruithof, PharmD, Christi M.J. Steendam, MD, PhD, René J. Boosman, PhD, Ron H.J. Mathijssen, MD, PhD, Vivianne C.G. Tjan-Heijnen, MD, PhD, Johanna H.M. Driessen, PhD, Safiye Dursun, MD, Egbert F. Smit, MD, PhD, Anne-Marie C. Dingemans, MD, PhD, Robin M.J.M. van Geel, PharmD, PhD, Sander Croes, PharmD, PhD, Lizza E.L. Hendriks, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100656- (2024)
Introduction: Brain metastases (BM) are common in patients with advanced EGFR-mutated (EGFRm+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic
Externí odkaz:
https://doaj.org/article/b8cb56c1a21d4838abe7a2a929f0a009
Autor:
Karlijn Verkerk, Birgit S. Geurts, Laurien J. Zeverijn, Vincent van der Noort, Henk M.W. Verheul, John B.A.G. Haanen, Astrid A.M. van der Veldt, Ferry A.L.M. Eskens, Maureen J.B. Aarts, Carla M.L. van Herpen, Mathilde Jalving, Jourik A. Gietema, Lot A. Devriese, Mariette Labots, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Egbert F. Smit, Haiko J. Bloemendal
Publikováno v:
The Lancet Regional Health. Europe, Vol 39, Iss , Pp 100875- (2024)
Summary: Background: The DRUG Access Protocol provides patients with cancer access to registered anti-cancer drugs that are awaiting reimbursement in the Netherlands and simultaneously collects prospective real-world data (RWD). Here, we present RWD
Externí odkaz:
https://doaj.org/article/fc99db69ccab44d8b32b3ad075d188c3
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/b01d9d85a526473fad40622c3a74faba
Autor:
Karlijn Hummelink, Vincent van der Noort, Mirte Muller, Robert D Schouten, Michel M van den Heuvel, Daniela S Thommen, Egbert F Smit, Gerrit A Meijer, Kim Monkhorst
Publikováno v:
PLoS ONE, Vol 19, Iss 7, p e0293707 (2024)
BackgroundThe efficacy of PD-1 blocking agents in advanced NSCLC has shown prolonged effectiveness, but only in a minority of patients. Multiple biomarkers have been explored to predict treatment benefit, yet their combined performance remains inadeq
Externí odkaz:
https://doaj.org/article/6b18e0bcb87f45658fff43824048aa27
Autor:
Myriam Mirza, Aseem Shrivastava, Cecile Matthews, Natasha Leighl, Calvin S. H. Ng, David Planchard, Sanjay Popat, Julia Rotow, Egbert F. Smit, Ross Soo, Masahiro Tsuboi, Fan Yang, Brendon Stiles, Christian Grohe, Yi-Long Wu
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
IntroductionOsimertinib is recommended by major guidelines for use in the adjuvant setting in patients with EGFR mutation-positive NSCLC following the significant improvement in disease-free survival observed in the Phase III ADAURA trials. Due to li
Externí odkaz:
https://doaj.org/article/16b99c860cb44565b5aca42740985756
Autor:
Frank J. Borm, Jasper Smit, Joyce Bakker, Maurits Wondergem, Egbert F. Smit, Adrianus J. de Langen, Tanja D. de Gruijl
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTBetter biomarkers for programmed death - (ligand) 1 (PD-(L)1) checkpoint blockade in non-small cell lung cancer (NSCLC) are needed. We explored the predictive value of early response evaluation using Fluor-18-deoxyglucose positron emission to
Externí odkaz:
https://doaj.org/article/b3bac891f09a4fdfb2e410416d7ae4df